CIMAB S.A. – Product Pipeline Review – 2014

1
CIMAB S.A. Product Pipeline Review 2014
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_rnrmarketresearch.com
with your contact details and questions if any.
Single User License US 1500 Corporate User
License US 4500
2
CIMAB S.A. Product Pipeline Review 2014

• Summary
• Researchers, CIMAB S.A. Product Pipeline
  Review 2014', provides an overview of the CIMAB
  S.A.s pharmaceutical research and development
  focus.
• This report provides comprehensive information on
  the current therapeutic developmental pipeline of
  CIMAB S.A.s, complete with comparative analysis
  at various stages, therapeutics assessment by
  drug target, mechanism of action (MoA), route of
  administration (RoA) and molecule type. It also
  reviews latest updates, and featured news and
  press releases, along with special features on
  late-stage and discontinued projects.
• Researchers report features investigational
  drugs from across globe covering over 20 therapy
  areas and nearly 3,000 indications.

3
CIMAB S.A. Product Pipeline Review 2014

• The report is built using data and information
  sourced from Researchers proprietary databases,
  Company/University websites, SEC filings,
  investor presentations and featured press
  releases from company/university sites and
  industry-specific third party sources, put
  together by Researchers team. Drug
  profiles/records featured in the report undergoes
  periodic updation following a stringent set of
  processes that ensures that all the profiles are
  updated with the latest set of information.
  Additionally, processes including live news
  deals tracking, browser based alert-box and
  clinical trials registries tracking ensure that
  the most recent developments are captured on a
  real time basis.
• The report enhances decision making capabilities
  and help to create effective counter strategies
  to gain competitive advantage. It strengthens RD
  pipelines by identifying new targets and MOAs to
  produce first-in-class and best-in-class products.

4
CIMAB S.A. Product Pipeline Review 2014

• Scope
• - The report provides brief overview of CIMAB
  S.A. including business description, key
  information and facts, and its locations and
  subsidiaries- The report reviews current
  pipeline of CIMAB S.A.s human therapeutic
  division and enlists all their major and minor
  projects- The report features product
  description and descriptive mechanism of action
  for key pipeline products along with the
  products developmental history and major
  milestones - Special feature on out-licensed and
  partnered product portfolio- The report
  summarizes all the dormant and discontinued
  pipeline projects
• Complete report is available _at_ http//www.rnrmarke
  tresearch.com/cimab-s-a-product-pipeline-review-20
  14-market-report.html .

5
CIMAB S.A. Product Pipeline Review 2014

• Reasons to Buy
• - Evaluate CIMAB S.A.s strategic position with
  total access to detailed information on its
  product pipeline- Assess the growth potential of
  CIMAB S.A. in its therapy areas of focus-
  Identify new drug targets and therapeutic classes
  in the CIMAB S.A.s RD portfolio and develop key
  strategic initiatives to reinforce pipeline in
  those areas- Exploit in-licensing opportunities
  by identifying windows of opportunity to fill
  portfolio gaps- Develop strategic initiatives by
  understanding the focus areas of CIMAB S.A. and
  exploit collaboration and partnership
  opportunities- Identify emerging players with
  potentially strong product portfolio and create
  effective counter-strategies to gain competitive
  advantage
• Buy a copy of this report _at_ http//www.rnrmarketre
  search.com/contacts/purchase?rname235068 .

6
CIMAB S.A. Product Pipeline Review 2014

• For more details contact Mr. Ritesh Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.